Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · USD

$1.19

+0.02 (+1.7%)· Recorded snapshot

Market cap	51.9M
Net income (ttm)	-20.1M
EPS (ttm)	-$0.51
Shares out	43.6M
Volume	378,101
Beta	0.19

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -20.1M
EPS (ttm): -$0.51
Market cap: 51.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-268.3

P25 n/aP50 n/aP75 n/a

ROIC-148.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GANX indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001819411
Company name	Gain Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	36269B105
Earnings date	2026-11-11
Earnings time	bmo
Employees	21
Employees change	-4
Employees growth	-16%
Enterprise value	$39.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
Industry	Biotechnology
IPO date	2021-03-18
Is primary listing	Yes
Is SPAC	No
ISIN number	US36269B1052
Last 10-K release date	2026-03-26
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$51.9M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$1.19
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	GANX
U.S. state	Maryland
Website	https://gaintherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-42.79%
FCF / EV yield	-49.11%
FCF yield	-37.12%
P/B ratio	4.49x
Price / tangible book value	4.55x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-957,441
ROA	-95.51%
ROA (5Y)	-57.16%
ROCE	-160.97%
ROE	-268.3%
ROE (5Y)	-127.09%
ROIC	-148.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	2
Net income growth quarters	1
Net income growth years	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$49,531
EBIT	$-19.3M
EBITDA	$-19.2M
EPS	$-0.51
FCF per share	$-0.43
Financing cash flow	$25.4M
Free cash flow	$-19M
Free cash flow minus SBC	$-20.8M
Gross profit	$-10M
Income taxes	$906,540
Net borrowing	$-100,843
Net cash flow	$6.4M
Net income	$-20.1M
Operating cash flow minus SBC	$-20.8M
Operating income	$-19.3M
Stock-based compensation	$1.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.26
Debt / equity	0.05
Long-term assets	$452,191
Long-term liabilities	$696,043
Net cash (debt)	$12.5M
Net cash / market cap	24.43%
Net cash growth	107.44%
Net debt / equity	-1.1
Piotroski F-Score	3
Property, plant and equipment	$313,887
Shareholders' equity	$11.3M
Tangible book value	$11.2M
Tangible book value per share	$0.26
Total assets	$15.4M
Total cash	$13.1M
Total debt	$609,874
Total liabilities	$4.1M
WACC	5.26%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$15M
Current liabilities	$3.4M
Current ratio	4.36
Net working capital	$-1.3M
Quick ratio	4.11
Working capital	$11.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-39.34%
Dividend yield	0%
Shareholder yield	-39.34%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.78
1D price change	1.71%
1M price change	-33.43%
1M total return	-33.43%
1W price change	-0.42%
1W total return	-0.42%
1Y price change	-39.23%
1Y return CAGR	-39.25%
1Y total return	-39.23%
20-day SMA	$1.42
200-day SMA	$1.87
3M price change	-36.29%
3M total return	-36.29%
3Y price change	-59%
3Y return CAGR	-25.7%
3Y total return	-59%
50-day SMA	$1.66
50-day SMA vs 200-day SMA	50under200
52-week high	$4.34
52-week high date	2025-12-11
52-week low	$1.14
52-week low date	2026-10-27
5Y price change	-83.07%
5Y return CAGR	-29.9%
5Y total return	-83.07%
6M price change	-39.23%
6M total return	-39.23%
All-time high	$17.93
All-time high date	2021-04-12
All-time low	$0.89
All-time low date	2024-08-13
Average true range (ATR)	$0.10
Average volume	625.3K
Beta (1Y)	2.58
Beta (2Y)	1.7
Beta (5Y)	0.19
Change from 52-week high	-72.58%
Change from 52-week low	4.39%
Change from all-time high	-93.39%
Change from all-time low	33.15%
Change from open	1.71%
Day's gap	0%
Dollar volume	$449,940
High price	$1.19
Low price	$1.16
Monthly RSI	39.3
Open price	$1.17
Position in 52-week range	100%
Premarket change	-0.06%
Premarket close	$1.17
Premarket price	$1.17
Premarket volume	930
Previous close	$1.17
Price vs 150-day SMA	-33.39%
Price vs 20-day SMA	-16.25%
Price vs 200-day SMA	-36.63%
Price vs 50-day SMA	-28.44%
Relative volume	0.6
Return from IPO open	-89.57%
Return from IPO price	-89.36%
RSI	29.32
Sharpe ratio	0.05
Sharpe ratio (3Y)	0.14
Sharpe ratio (5Y)	-0.01
Sortino ratio	0.13
Sortino ratio (3Y)	0.26
Sortino ratio (5Y)	0.05
Volume	378.1K
Weekly RSI	33.91
YTD price change	-63.2%
YTD total return	-63.2%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	42.6M
Float percentage	97.69%
Shares change (QoQ)	1.54%
Shares change (YoY)	39.34%
Shares held by insiders	2.31%
Shares held by institutions	20.38%
Shares outstanding	43.6M
Short % of float	7.49%
Short % of shares	7.31%
Short ratio	7.3 days

Deeper analysis on GANX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GANX report

Is a complete GANX research report available?

No complete published report is available for Gain Therapeutics, Inc. (GANX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Gain Therapeutics, Inc. (GANX)

Price

Financial snapshot

Fair-value bridge

Latest news · GANX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GANX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GANX

Frequently asked questions